PRTK Paratek Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 18 December 2019 Paratek Awarded BARDA Project BioShield Contract for NUZYRA®

   - Total award valued at up to $285 million  - Paratek to host a conference call today, December 18, 2019 at 5:30 p.m. EST BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a

2. 02 December 2019 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

   BOSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

3. 12 November 2019 Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019

   -- Third Quarter 2019 NUZYRA® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million -- -- Oral-only CABP Pharmacokinetics Study Initiated-- BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Paratek

4. 01 November 2019 Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

   BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

5. 31 October 2019 Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections

   BOSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced

6. 01 October 2019 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

   BOSTON, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

7. 01 October 2019 Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

   WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven

8. 09 September 2019 Paratek Mourns Passing of Co-founder Dr. Stuart Levy

   BOSTON, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) mourns the loss of Stuart Levy, M.D., who passed way last week. Dr. Levy co-founded the company more than two decades ago along

9. 04 September 2019 Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

   BOSTON, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

10. 03 September 2019 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today

11. 26 August 2019 Paratek Pharmaceuticals to Present at Robert W. Baird's 2019 Global Healthcare Conference

    BOSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today